KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) FCF Margin (2017 - 2025)

Sarepta Therapeutics has reported FCF Margin over the past 12 years, most recently at 28.81% for Q4 2025.

  • For Q4 2025, FCF Margin rose 2062.0% year-over-year to 28.81%; the TTM value through Dec 2025 reached 13.99%, up 403.0%, while the annual FY2025 figure was 13.99%, 403.0% up from the prior year.
  • FCF Margin for Q4 2025 was 28.81% at Sarepta Therapeutics, up from 9.39% in the prior quarter.
  • Over five years, FCF Margin peaked at 37.56% in Q2 2025 and troughed at 994.69% in Q1 2023.
  • A 5-year average of 140.7% and a median of 48.65% in 2022 define the central range for FCF Margin.
  • On a YoY basis, FCF Margin climbed as much as 110080bps in 2021 and fell as far as -481483bps in 2021.
  • Year by year, FCF Margin stood at 15.65% in 2021, then increased by 17bps to 12.92% in 2022, then skyrocketed by 47bps to 6.84% in 2023, then soared by 220bps to 8.2% in 2024, then skyrocketed by 252bps to 28.81% in 2025.
  • Business Quant data shows FCF Margin for SRPT at 28.81% in Q4 2025, 9.39% in Q3 2025, and 37.56% in Q2 2025.